Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InvestisBio Completes $296 Million IPO on the Shanghai STAR Board

publication date: Jul 25, 2022

Shanghai’s InvestisBio raised $296 million in a Shanghai STAR Board IPO, giving the company a market capitalization of $1.5 billion. The company has three clinical-stage assets and five projects in pre-clinical development, all of them developed in-house. The NDA filing for its lead product, a third-gen EGFR inhibitor targeting non-small cell lung cancer, has been accepted for review by China’s NMPA. Before InvestisBio’s debut offering, there have been only two IPOs on the STAR Board in 2022: RemeGen’s $410 million initial offering in early April and January’s Mabwell Bio $547 million IPO. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital